Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 4 (2007), Issue 1 (January)

1. Postmenopausal hormone replacement therapy: endometrial and breast effects.
   Adv Anat Pathol, 14(1): 17-24. [Abstract] [Full-text]
2. Neurotrophic factors minimize the retinal toxicity of verteporfin photodynamic therapy.
   Invest Ophthalmol Vis Sci, 48(1): 430-7. [Abstract] [Full-text]
3. Effects of photodynamic therapy using 5-aminolevulinic acid on cultured human adenomyosis-derived cells.
   Fertil Steril, 87(1): 33-8. [Abstract] [Full-text]
4. Possible gender-related differences in the risk-to-benefit ratio of thrombolysis for acute submassive pulmonary embolism.
   Am J Cardiol, 99(1): 103-7. [Abstract] [Full-text]
5. Delayed fluid resuscitation in hemorrhagic shock induces proinflammatory cytokine response.
   Ann Emerg Med, 49(1): 37-44. [Abstract] [Full-text]
6. Microbicide applicators: understanding design preferences among women in the dominican republic and South Africa.
   Sex Transm Dis, 34(1): 15-9. [Abstract] [Full-text]
7. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
   Ophthalmology, 114(1): 162-9. [Abstract] [Full-text]
8. Induction of apoptosis in HaCaT cells by photodynamic therapy with chlorin e6 or pheophorbide a.
   Skin Pharmacol Physiol, 20(1): 3-9. [Abstract] [Full-text]
9. Feasibility of concurrent adjuvant chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer.
   J Surg Oncol, 95(1): 45-50. [Abstract] [Full-text]
10. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.
    Cancer, 109(1): 93-9. [Abstract] [Full-text]
11. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
    Cancer, 109(1): 33-40. [Abstract] [Full-text]
12. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
    J Surg Oncol, 95(1): 22-7. [Abstract] [Full-text]
13. Recanalization after thrombolysis in stroke patients: predictors and prognostic implications.
    Neurology, 68(1): 39-44. [Abstract] [Full-text]
14. Prevention of pediatric medication errors by hospital pharmacists and the potential benefit of computerized physician order entry.
    Pediatrics, 119(1): e77-85. [Abstract] [Full-text]
15. To what extent do pediatricians accept computer-based dosing suggestions?
    Pediatrics, 119(1): e69-75. [Abstract] [Full-text]
16. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Clin Infect Dis, 44(3): 441-6. [Abstract] [Full-text]
17. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism.
    Arch Intern Med, 167(1): 74-80. [Abstract] [Full-text]
18. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
    Cancer Res, 67(1): 346-53. [Abstract] [Full-text]
19. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation.
    Cancer Res, 67(1): 339-45. [Abstract] [Full-text]
20. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Cancer Res, 67(1): 281-8. [Abstract] [Full-text]
21. Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer.
    Cancer Res, 67(1): 269-75. [Abstract] [Full-text]
22. Antibiotic prophylaxis for arthroscopy of the knee: is it necessary?
    Arthroscopy, 23(1): 4-6. [Abstract] [Full-text]
23. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
    Br J Cancer, 96(1): 38-43. [Abstract] [Full-text]
24. Wait times for breast cancer care.
    Br J Cancer, 96(1): 162-8. [Abstract] [Full-text]
25. A prospective study of postmenopausal hormone use and ovarian cancer risk.
    Br J Cancer, 96(1): 151-6. [Abstract] [Full-text]
26. Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.
    Br J Cancer, 96(1): 21-8. [Abstract] [Full-text]
27. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells.
    Br J Cancer, 96(1): 73-81. [Abstract] [Full-text]
28. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
    Br J Cancer, 96(1): 44-8. [Abstract] [Full-text]
29. Potentiation of photodynamic therapy of cancer by complement: the effect of gamma-inulin.
    Br J Cancer, 96(1): 67-72. [Abstract] [Full-text]
30. Role of chemotherapy resistance genes in outcome of neuroblastoma.
    Pediatr Blood Cancer, 48(3): 311-7. [Abstract] [Full-text]
31. Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
    Pediatr Blood Cancer, 48(3): 262-7. [Abstract] [Full-text]
32. Pre-radiation chemotherapy with response-based radiation therapy in children with central nervous system germ cell tumors: a report from the Children's Oncology Group.
    Pediatr Blood Cancer, 48(3): 285-91. [Abstract] [Full-text]
33. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
    Pediatr Blood Cancer, 48(3): 278-84. [Abstract] [Full-text]
34. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
    Pediatr Blood Cancer, 48(3): 330-2. [Abstract] [Full-text]
35. Hypertonic saline and pentoxifylline reduces hemorrhagic shock resuscitation-induced pulmonary inflammation through attenuation of neutrophil degranulation and proinflammatory mediator synthesis.
    J Trauma, 62(1): 104-11. [Abstract] [Full-text]
36. Intraoperative versus postoperative electrochemotherapy in high grade soft tissue sarcomas: a preliminary study in a spontaneous feline model.
    Cancer Chemother Pharmacol, 59(3): 375-81. [Abstract] [Full-text]
37. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
    Lancet, 369(9556): 123-31. [Abstract] [Full-text]
38. Assessment of bleeding events in clinical trials--proposal of a new classification.
    Am J Cardiol, 99(2): 288-90. [Abstract] [Full-text]
39. The evolving pattern of symptomatic coronary artery disease in the United States and Canada: baseline characteristics of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial.
    Am J Cardiol, 99(2): 208-12. [Abstract] [Full-text]
40. Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
    Anaesthesia, 62(2): 186-9. [Abstract] [Full-text]
41. A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
    Cancer Chemother Pharmacol, 59(4): 549-57. [Abstract] [Full-text]
42. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
    Cancer Chemother Pharmacol, 59(4): 515-25. [Abstract] [Full-text]
43. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
    Cancer Chemother Pharmacol, 59(4): 467-75. [Abstract] [Full-text]
44. Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.
    Cancer Chemother Pharmacol, 59(4): 477-84. [Abstract] [Full-text]
45. Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol, 59(4): 419-27. [Abstract] [Full-text]
46. The relationship between temporal discounting and the prisoner's dilemma game in intranasal abusers of prescription opioids.
    Drug Alcohol Depend, 87(1): 94-7. [Abstract] [Full-text]
47. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
    J Natl Cancer Inst, 99(2): 112-28. [Abstract] [Full-text]
48. Congenital hypothyroid female pax8-deficient mice are infertile despite thyroid hormone replacement therapy.
    Endocrinology, 148(2): 719-25. [Abstract] [Full-text]
49. Design and characterization of a platelet-targeted plasminogen activator with enhanced thrombolytic and antithrombotic potency.
    Biotechnol Appl Biochem, 46: 115-25. [Abstract] [Full-text]
50. Biocidal efficacy, biofilm-controlling function, and controlled release effect of chloromelamine-based bioresponsive fibrous materials.
    Biomaterials, 28(9): 1597-609. [Abstract] [Full-text]
51. Controlled release of vancomycin from thin sol-gel films on titanium alloy fracture plate material.
    Biomaterials, 28(9): 1721-9. [Abstract] [Full-text]
52. Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles.
    Biomaterials, 28(9): 1730-40. [Abstract] [Full-text]
53. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease.
    J Clin Oncol, 25(3): 332-7. [Abstract] [Full-text]
54. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
    J Clin Oncol, 25(3): 326-31. [Abstract] [Full-text]
55. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).
    J Clin Oncol, 25(3): 313-8. [Abstract] [Full-text]
56. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
    J Clin Oncol, 25(3): 247-56. [Abstract] [Full-text]
57. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    J Clin Oncol, 25(3): 263-70. [Abstract] [Full-text]
58. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer.
    Cancer Res, 67(2): 818-26. [Abstract] [Full-text]
59. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
    Cancer Res, 67(2): 792-801. [Abstract] [Full-text]
60. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Cancer Res, 67(2): 782-91. [Abstract] [Full-text]
61. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications.
    Clin J Pain, 23(2): 180-95. [Abstract] [Full-text]
62. Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
    Int J Radiat Oncol Biol Phys, 67(2): 505-11. [Abstract] [Full-text]
63. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
    Int J Radiat Oncol Biol Phys, 67(2): 397-404. [Abstract] [Full-text]
64. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
    Int J Radiat Oncol Biol Phys, 67(2): 405-9. [Abstract] [Full-text]
65. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy.
    Clin Infect Dis, 44(4): 599-604. [Abstract] [Full-text]
66. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy.
    Clin Infect Dis, 44(4): 584-90. [Abstract] [Full-text]
67. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.
    Br J Ophthalmol, 91(2): 174-9. [Abstract] [Full-text]
68. Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes.
    Br J Ophthalmol, 91(2): 166-73. [Abstract] [Full-text]
69. Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated.
    Emerg Med J, 24(2): 96-9. [Abstract] [Full-text]
70. Acute lymphoblastic leukemia presenting as acute renal failure.
    Nat Clin Pract Nephrol, 3(2): 106-10. [Abstract] [Full-text]
71. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
    Int J Cancer, 120(5): 1141-9. [Abstract] [Full-text]
72. Small volume enemas do not accelerate meconium evacuation in very low birth weight infants.
    J Pediatr Gastroenterol Nutr, 44(2): 270-3. [Abstract] [Full-text]
73. Efficacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diarrhea.
    J Pediatr Gastroenterol Nutr, 44(2): 258-64. [Abstract] [Full-text]
74. Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal stem cells.
    Biomaterials, 28(10): 1830-7. [Abstract] [Full-text]
75. High-loading nanosized micelles of copoly(styrene-maleic acid)-zinc protoporphyrin for targeted delivery of a potent heme oxygenase inhibitor.
    Biomaterials, 28(10): 1871-81. [Abstract] [Full-text]
76. Anti-inflammatory function of an in situ cross-linkable conjugate hydrogel of hyaluronic acid and dexamethasone.
    Biomaterials, 28(10): 1778-86. [Abstract] [Full-text]
77. Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery.
    Biomaterials, 28(10): 1889-99. [Abstract] [Full-text]
78. Thyroid hormone (T3)-modification of polyethyleneglycol (PEG)-polyethyleneimine (PEI) graft copolymers for improved gene delivery to hepatocytes.
    Biomaterials, 28(10): 1900-11. [Abstract] [Full-text]
79. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease.
    Biomaterials, 28(10): 1882-8. [Abstract] [Full-text]
80. Modulation of protein delivery from modular polymer scaffolds.
    Biomaterials, 28(10): 1862-70. [Abstract] [Full-text]
81. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
    J Thorac Cardiovasc Surg, 133(2): 352-63. [Abstract] [Full-text]
82. Data acquisition for the histoculture drug response assay in lung cancer.
    J Thorac Cardiovasc Surg, 133(2): 303-8. [Abstract] [Full-text]
83. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
    J Clin Oncol, 25(4): 437-43. [Abstract] [Full-text]
84. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06.
    J Clin Oncol, 25(4): 424-30. [Abstract] [Full-text]
85. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
    J Clin Oncol, 25(4): 418-23. [Abstract] [Full-text]
86. Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial.
    J Clin Oncol, 25(4): 405-10. [Abstract] [Full-text]
87. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
    J Clin Oncol, 25(4): 399-404. [Abstract] [Full-text]
88. Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome.
    J Clin Oncol, 25(4): 370-5. [Abstract] [Full-text]
89. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    J Clin Oncol, 25(4): 362-9. [Abstract] [Full-text]
90. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
    J Clin Oncol, 25(4): 411-7. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.